<DOC>
	<DOC>NCT02601287</DOC>
	<brief_summary>This is a safety and efficacy study of BOTOX® (Botulinum Toxin Type A) in the Treatment of Adult Korean Patients with Urinary Incontinence due to Neurogenic Detrusor Overactivity or Overactive Bladder.</brief_summary>
	<brief_title>A Safety and Efficacy Study of Botulinum Toxin Type A (BOTOX®) to Treat Urinary Incontinence Due to Neurogenic Detrusor Overactivity or Overactive Bladder in Korean Patients</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Urinary incontinence as a result of neurogenic overactive bladder due to spinal cord injury or multiple sclerosis Symptoms of urge urinary incontinence, urgency, and frequency due to overactive bladder Myasthenia gravis, EatonLambert syndrome, or amyotrophic lateral sclerosis Use of botulinum toxin therapy of any serotype in the 3 months prior to screening Has acute urinary retention who do not routinely perform clean intermittent selfcatheterization (CIC)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>